• Organic growth of 6.8% at constant exchange rates and scope of consolidation over the first nine months of the year:
    • €1,928 million in sales
    • Up 10.3% as reported
  • Acceleration of organic growth in sales to reach 9.6% in the third quarter driven by strong momentum across all Regions
  • 2019 targets:
    • Organic growth in sales of around 7%
    • Contributive operating income before non-recurring items of between €385 million and €400 million

Alexandre Mérieux, Chairman and Chief Executive Officer, said: 'bioMérieux performed well in the third quarter of 2019. Fast-paced growth continued, driven primarily by a solid increase in reagent sales that reached 8% growth for the first nine months of the year. Given our business outlook and a high basis of comparison in the fourth quarter, organic growth in sales should come in at around 7.0% for the full year and our target margin is confirmed.'

Attachments

  • Original document
  • Permalink

Disclaimer

BioMérieux SA published this content on 22 October 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 October 2019 05:44:04 UTC